Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
This was a single-centre, single-arm, non-blinded, prospective study using 20 patients with advanced metastatic GI malignancies recruited to treat patients with advanced metastatic GI malignancies with 177Lu-CTR-FAPI to assess the safety of 177Lu-CTR-FAPI in advanced metastatic GI malignancies; this included radiation therapy dosimetry and initial treatment Determination of Effectiveness